Compared with daily oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC), long-acting cabotegravir (CAB-LA) maintained robust efficacy, regardless of sexually transmitted infection (STI) incidence, according to study findings published in Clinical Infectious Diseases.
Researchers conducted an analysis of a double-blind, double-dummy randomized controlled trial (HPTN 083) to examine whether CAB-LA maintained protective efficacy when bacterial STIs were present. Transgender women and cisgender men who have sex with men were assigned 1:1 to receive active CAB-LA with TDF/FTC placebo or active TDF/FTC with CAB-LA placebo.
Read the full story at Infectious Disease Advisor.
Source : Infectious Disease Advisor
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.